EZH2 promotes chemoresistance in colorectal cancer by inhibiting autophagy through NRP1 suppression
Biochemical Journal · 2025
DOI: 10.1042/bcj20240607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2025. Verfasst von Hong Deng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery (Gastrointestinal Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Colorectal Neoplasms, Neuropilin-1, Autophagy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SWMU | Affiliated Hospital of Southwest Medical University (The Affiliated Hospital of Southwest Medical University).
Abstract (Originalsprache)
Colorectal cancer (CRC) is characterized by aggressive tumor growth and chemoresistance, with enhancer of zeste homolog 2 (EZH2) serving a pivotal role in these processes. However, the mechanisms by which it drives tumor proliferation and therapeutic resistance through autophagy regulation remain unclear. Here, we demonstrated that EZH2 expression is elevated in CRC tissues and cell lines, correlating with chemoresistance and diagnostic potential (area under the curve = 0.968). EZH2 knockdown markedly reduced CRC cell proliferation, while its overexpression promoted tumor growth and increased resistance to irinotecan. Mechanistically, EZH2 suppressed autophagy in CRC cells, a process linked to chemosensitivity, by directly regulating LC3bI/II expression. Notably, EZH2 enhanced the neuropilin-1 (NRP1) level by binding to the NRP1 promoter, thereby promoting tumor proliferation and irinotecan resistance through autophagy inhibition. NRP1 depletion partially reversed these effects, underscoring the crucial role of the EZH2-NRP1 axis in CRC. Our findings highlight that targeting the EZH2-NRP1 interaction could represent a novel therapeutic approach to overcoming chemoresistance in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery (Gastrointestinal Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
- Inflammation and Allergic Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
- Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.
ORCID-Profile: Lei Ren
Förderung
- SWMU | Affiliated Hospital of Southwest Medical University (The Affiliated Hospital of Southwest Medical University)
Zitieren
APA
Deng, H., Xu, Q., Zhang, Q., Liu, C., & Ren, L. (2025). EZH2 promotes chemoresistance in colorectal cancer by inhibiting autophagy through NRP1 suppression. Biochemical Journal. https://doi.org/10.1042/bcj20240607
Vancouver
Deng H, Xu Q, Zhang Q, Liu C, Ren L. EZH2 promotes chemoresistance in colorectal cancer by inhibiting autophagy through NRP1 suppression. Biochemical Journal. 2025. doi:10.1042/bcj20240607
BibTeX
@article{Deng2025,
author = {Deng, Hong and Xu, Qin and Zhang, Qiang and Liu, Chunfeng and Ren, Lei},
title = {EZH2 promotes chemoresistance in colorectal cancer by inhibiting autophagy through NRP1 suppression},
journal = {Biochemical Journal},
year = {2025},
doi = {10.1042/bcj20240607}
}
EUVIMED